Core Viewpoint - ImmuCell Corporation has successfully refinanced a portion of its bank debt, which is expected to improve its financial position and operational flexibility [1][2]. Financial Summary - The company secured a new loan from Maine Community Bank (MCB) amounting to $2,327,119 at a fixed interest rate of 6.5% per annum [2]. - The proceeds were utilized to pay off an existing loan from MCB with a balance of $1,525,852 at 7% interest and another loan from the Finance Authority of Maine (FAME) with a balance of $768,209 at 8% interest [2]. - The paid-off loans had balloon principal payments totaling approximately $1,946,000 due in the third quarter of 2026 [2]. - The new loan features a five-year amortization schedule, concluding in the third quarter of 2030 [2]. Management Commentary - The President and CEO of ImmuCell expressed appreciation for the ongoing relationship with MCB and acknowledged the support from FAME, particularly during mid-2023 [3]. - By paying off the FAME loan early, the company aims to free up funds for other uses within the State of Maine [3]. Upcoming Events - ImmuCell plans to host a conference call on August 15, 2025, to discuss the unaudited financial results for the quarter ended June 30, 2025 [3]. Company Overview - ImmuCell Corporation focuses on developing and marketing products that enhance the health and productivity of dairy and beef cattle [4]. - The company manufactures First Defense, which provides Immediate Immunity™ to newborn calves, and is developing Re-Tain, a treatment for subclinical mastitis in dairy cows [4].